Synthesis and biological evaluation of atropisomeric tetrahydroisoquinolines overcoming docetaxel resistance in triple-negative human breast cancer cells

被引:0
|
作者
Song, Jayoung [1 ]
Kim, Ahreum [2 ]
Hong, Intaek [2 ]
Kim, Sangji [2 ]
Byun, Woong Sub [1 ]
Lee, Hyun Soo [3 ]
Kim, Hyung Sik [2 ]
Lee, Sang Kook [1 ]
Kwon, Yongseok [2 ]
机构
[1] Seoul Natl Univ, Nat Prod Res Inst, Coll Pharm, Seoul 08826, South Korea
[2] Sungkyunkwan Univ, Sch Pharm, Suwon 16419, South Korea
[3] Sogang Univ, Dept Chem, Seoul 04107, South Korea
基金
新加坡国家研究基金会;
关键词
Apoptosis; Atropisomerism; Docetaxel resistance; Isoquinolines; STAT3; Triple-negative breast cancer; DRUG; THERMOCHEMISTRY; TRANSFORMATION; CHEMISTRY; CHIRALITY;
D O I
10.1016/j.bioorg.2023.106573
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Herein, atropisomeric 8-aryltetrahydroisoquinolines have been synthesized and biologically evaluated. Based on our structure-activity relationship study, a highly bioactive racemic compound has been produced, and it exhibited high antiproliferative activities against various cancer cell lines, including docetaxel-resistant breast cancer cell lines. Each enantiomer can be synthesized in an enantioselective manner by employing the chiral phosphoric acid-catalyzed atroposelective Pictet-Spengler cyclization. An axially (R)-configured enantiomer showed a higher biological activity compared with the axially (S)-configured enantiomer. Further biological studies suggested that the (R)-enantiomer overcomes docetaxel resistance via the downregulation of signal transducer and activator of transcription 3 activation and consequently induces cellular apoptosis in docetaxel-resistant triple-negative breast cancer cell lines.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Activity of dasatinib with chemotherapy in triple-negative breast cancer cells
    Tryfonopoulos, D.
    O'Donovan, N.
    Corkery, B.
    Clynes, M.
    Crown, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study
    Passos, Ioannis D.
    Papadimitriou, Dimochristos
    Katsouda, Areti
    Papavasileiou, Georgios E.
    Galatas, Apostolos
    Tzitzis, Panagiotis
    Mpakosi, Alexandra
    Mironidou-Tzouveleki, Maria
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (08)
  • [43] In vitro photodynamic therapy of triple-negative breast cancer cells
    Scarbrough, Megan
    Bradshaw, Joseph E.
    Hayes, Timothy E.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [44] Efp promotes growth of triple-negative breast cancer cells
    Sato, Wataru
    Ikeda, Kazuhiro
    Gotoh, Noriko
    Inoue, Satoshi
    Horie, Kuniko
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2022, 624 : 81 - 88
  • [45] DSTYK Enhances Chemoresistance in Triple-Negative Breast Cancer Cells
    Ogbu, Stella C.
    Rojas, Samuel
    Weaver, John
    Musich, Phillip R.
    Zhang, Jinyu
    Yao, Zhi Q.
    Jiang, Yong
    CELLS, 2022, 11 (01)
  • [46] Combination chemotherapy with docetaxel and carboplatin in triple-negative breast cancer: a single institution experience
    Kurbacher, C. M.
    Kurbacher, J. A.
    Braun, K.
    Mehra, S.
    Schweitzer, C.
    Arenz, P. N.
    ONKOLOGIE, 2010, 33 : 29 - 29
  • [47] Irreversible Electroporation of Aggressive Triple-Negative Breast Cancer Cells
    Raman, Vishak
    Camarillo, Ignacio
    Garner, Allen
    Diwakar, Prasoon
    Madhivanan, S.
    Raakesh, M.
    Sundararajan, Raji
    2015 IEEE CONFERENCE ON ELECTRICAL INSULATION AND DIELECTRIC PHENOMENA (CEIDP), 2015, : 624 - 627
  • [48] Potentiation of the Anticancer Effects by Combining Docetaxel with Ku-0063794 against Triple-Negative Breast Cancer Cells
    Jeon, Ye-Won
    Kim, Ok-Hee
    Shin, Jin Sun
    Hong, Ha Eun
    Kim, Cho Hee
    Kim, Say-June
    CANCER RESEARCH AND TREATMENT, 2022, 54 (01): : 157 - 173
  • [49] Meroterpenoids From Ganoderma lucidum Mushrooms and Their Biological Roles in Insulin Resistance and Triple-Negative Breast Cancer
    Zhang, Jiao-Jiao
    Wang, Dai-Wei
    Cai, Dan
    Lu, Qing
    Cheng, Yong-Xian
    FRONTIERS IN CHEMISTRY, 2021, 9
  • [50] New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
    Han, Ye
    Yu, Xiaopeng
    Li, Shuqiang
    Tian, Ye
    Liu, Caigang
    FRONTIERS IN ONCOLOGY, 2020, 10